Advanced Search

Refine my results

Document type

Institution

Specific Collection

Language

Author

Domain

Keyword

    Sorted by: Date of deposit
    2 results 1
    Université de Fribourg

    Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer

    Lan, Qiang ; Peyvandi, Sanam ; Duffey, Nathalie ; Huang, Yu-Ting ; Barras, David ; Held, Werner ; Richard, François ; Delorenzi, Mauro ; Sotiriou, Christos ; Desmedt, Christine ; Lorusso, Girieca ; Rüegg, Curzio

    In: Oncogene, 2019, vol. 38, no. 15, p. 2814–2829

    Neoadjuvant and adjuvant chemotherapies provide survival benefits to breast cancer patients, in particular in estrogen receptor negative (ER−) cancers, by reducing rates of recurrences. It is assumed that the benefits of (neo)adjuvant chemotherapy are due to the killing of disseminated, residual cancer cells, however, there is no formal evidence for it. Here, we provide experimental...

    Université de Fribourg

    Arginase inhibition suppresses lung metastasis in the 4T1 breast cancer model independently of the immunomodulatory and anti-metastatic effects of VEGFR-2 blockade

    Secondini, Chiara ; Coquoz, Oriana ; Spagnuolo, Lorenzo ; Spinetti, Thibaud ; Peyvandi, Sanam ; Ciarloni, Laura ; Botta, Francesca ; Bourquin, Carole ; Rüegg, Curzio

    In: OncoImmunology, 2017, vol. 6, no. 6, p. e1316437

    Tumor angiogenesis promotes tumor growth and metastasis. Anti-angiogenic therapy in combination with chemotherapy is used for the treatment of metastatic cancers, including breast cancer but therapeutic benefits are limited. Mobilization and accumulation of myeloid-derived suppressor cells (MDSC) during tumor progression and therapy have been implicated in metastasis formation and resistance to...

    2 results 1